[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"colorectal-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:colorectal-cancer":33},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,595,0,25,[9,47,91,111,143,180,203,228,251,274,297,318,341,362,382,408,447,474,498,525,553,575,601,621,650],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100359833","pulmonary-suffusion-in-controlling-minimal-residual-disease-in-patients-with-sarcoma-or-colorectal-metastases-100359833",false,"NCT03965234","Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases","Phase I\u002F II Study of Pulmonary Suffusion to Control Minimal Residual Disease in Resectable or Ablatable Sarcoma or Colorectal Pulmonary Metastases","Inclusion Criteria:\n\n* Tumors metastatic to the lungs that are the focus of this protocol specifically:\n\n  * Colorectal carcinoma\n* Have an Eastern Cooperative Oncology Group (ECOG) performance status of =\\\u003C 2\n* Hemoglobin \\> 8.0 g\u002FL\n* Neutrophils \\> 1,500 uL\n* Platelets \\>= 100,000 uL\n* Creatinine clearance \\>= 30 mL\u002Fmin\n* Clinically diagnosed lung metastases(while preregistration histologic or cytologic confirmation is desirable, this may not be required in clinical scenarios where a biopsy may not change the need to resect suspicious lung nodules or the biopsy itself poses a risk for tumor seeding. In such cases, the diagnosis will be supported by rapid pathologic evaluations intraoperatively before proceeding with Suffusion) Given the emergence of other acceptable options to destroy lung metastases such as stereotactic body radiation therapy (SBRT) or microwave ablation, a hybrid approach to eliminate all sites of disease will be permitted; however, supplemental approaches should be delayed, if possible, until after the 30 day post-suffusion endpoint\n* Pulmonary function judged by the surgeon to be sufficient to tolerate the planned pulmonary metastasectomy. Testing is not required but generally is performed clinically and will be left to the discretion of the treating surgeon. The following are not required but serve as guidelines since they were used to determine eligibility for the Phase I protocol: EV1 \\>= 50% predicted\n* Diffusion capacity of the lung for carbon monoxide (DLCO) \\>= 50% predicted\n* Vital capacity (VC) \\>= 50% predicted\n* Ambulatory and resting oxygen (O2) saturation \\> 88%\n* Six minute walk \\>= 50 % of the expected distance\n* Surgeon affirmation that suffusion and resection or ablation of all nodules is technically feasible\n* Control of the primary tumor as determined by clinical assessment per standard of care; may include stable tumor status of primary tumor and other metastases, in the clinical judgement of the PI\u002Fconsulting physician.\n* Participants of child-bearing potential must agree to use adequate contraceptive methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately\n* Participant must understand the investigational nature of this study and sign an Independent Ethics Committee\u002FInstitutional Review Board approved written informed consent form prior to receiving any study related procedure\n\nExclusion Criteria:\n\n* Participants who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier\n* Participants with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events\n* Allergy, intolerance, or other serious reaction to chemotherapy drugs that may be used in the procedure\n* Pregnant or nursing female participants\n* Unwilling or unable to follow protocol requirements\n* Pulmonary metastases unable to be completely resected or ablated based on pre-registration review of imaging by a thoracic surgeon or proceduralist.\n* Any additional condition which in the Investigator's opinion deems the participant an unsuitable candidate to receive study drug or the suffusion technique, may include uncontrolled intercurrent illness and other conditions that, in the judgement of the PI\u002FPhysician, would limit compliance with the study requirements and have safety concerns\n* Received an investigational agent within 30 days prior to enrollment\n* Severe peripheral neuropathy","ALL","18 Years",{"count":20,"type":21},99,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","This phase I\u002FII trial studies the side effects of pulmonary suffusion in controlling minimal residual disease in patients with sarcoma or colorectal carcinoma that has spread to the lungs. Pulmonary suffusion is a minimally invasive delivery of chemotherapeutic agents like cisplatin to lung tissues. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Pulmonary suffusion may also be useful in avoiding later use of drugs by vein that demonstrate no effect on tumors when delivered locally.\n\nThe Phase 1 portion of the study has been completed.",[28,29,30,31,32,33],"Metastatic Bone Sarcoma","Metastatic Malignant Neoplasm in the Lung","Metastatic Soft Tissue Sarcoma","Metastatic Unresectable Sarcoma","Resectable Sarcoma","Colorectal Cancer","RECRUITING","2026-08-20",{"date":37,"type":38},"2026-08-21","ACTUAL",{"date":40,"type":38},"2020-07-16",{"date":42,"type":21},"2030-05-25",{"name":44,"class":45},"Roswell Park Cancer Institute","OTHER",1,{"id":48,"slug":49,"hasResults":12,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":58,"conditions":59,"keywords":71,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":90},"100639777","phase-1-a-first-in-human-study-of-hh160-in-patients-with-advanced-solid-tumors-100639777","NCT07623369","A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors","An Open-Label, Multicenter, Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Preliminary Antitumor Activity of HH160 Alone or in Combination With Other Antitumor Agents in Patients With Advanced or Metastatic Solid Tumors","Key Inclusion Criteria\n\n1. Adults aged 18 to 75 years with signed informed consent.\n2. Histologically or cytologically confirmed advanced solid tumors meeting phase-specific disease requirements.\n3. At least 1 measurable lesion per RECIST v1.1.\n4. Eastern Cooperative Oncology Group Performance Status (ECOG) Performance Status of 0 or 1 with life expectancy ≥ 12 weeks.\n5. Adequate organ function based on protocol-specified laboratory criteria.\n\nKey Exclusion Criteria\n\n1. Active leptomeningeal disease or uncontrolled\u002Funtreated brain metastases.\n2. History of severe hypersensitivity reactions to monoclonal antibodies, bispecific antibodies, trispecific antibodies, or study drug components.\n3. Other malignancy within 3 years prior to first dose, except specified curatively treated cancers.\n4. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring frequent drainage.\n5. Significant bleeding risk, severe coagulopathy, gastrointestinal hemorrhage, or recent pulmonary hemorrhage\u002Fhemoptysis.\n\nNOTE: Other eligibility criteria may apply.","75 Years",{"count":56,"type":21},299,[24],"This study is evaluating the safety, side effects, how the body processes HH160, and its early anticancer activity when given alone or with other cancer treatments in participants with advanced solid tumors. The study will also identify the recommended dose for future studies. The trial includes two phases and is expected to last about 4 years, with treatment and follow-up lasting approximately 6-12 months each.",[60,61,62,33,63,64,65,66,67,68,69,70],"Solid Tumor","Non-small Cell Lung Cancer","Hepatocellular Carcinoma","Head and Neck Squamous Cell Carcinoma","Renal Cell Carcinoma","Endometrial Cancer","Cervical Cancer","Small-cell Lung Cancer","Triple Negative Breast Cancer","Urothelial Carcinoma","Gastroesophageal Adenocarcinoma",[72,73,61,74,62,75,33,76,77,63,64,78,65,66,67,68,79,69,70,80],"HH160","PD-1×CTLA-4×VEGF-A Antibody","NSCLC","HCC","CRC","GEA","RCC","TNBC","Ovarian Cancer","2026-08-19",{"date":37,"type":38},{"date":84,"type":38},"2026-06-11",{"date":86,"type":21},"2028-08",{"name":88,"class":89},"Huahui Health","INDUSTRY",3,{"id":92,"slug":93,"hasResults":12,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":4,"eligibilityCriteria":97,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":98,"targetDuration":4,"studyType":22,"phases":100,"briefSummary":101,"conditions":102,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":103,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":110},"100611031","phase-2-a-study-to-test-dsp107-in-combination-with-atezolizumab-in-comparison-with-fruquintinib-as-a-new-treatment-for-colorectal-cancer-100611031","NCT07235293","A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.","A Randomized, Open-label, Phase 2b Study to Compare the Efficacy of DSP107 in Combination With Atezolizumab Versus Fruquintinib in Patients With Advanced Microsatellite Stable Colorectal Cancer","Inclusion Criteria:\n\n1. Are ≥ 18 years of age with a life expectancy of \\> 3 months.\n2. Participants with histologically confirmed, inoperable, MSS and\u002For pMMR CRC which has progressed to, or is intolerant to, specified therapies (and has received prior treatment with no more than 3 lines of therapy).\n3. Measurable disease per RECIST v1.1.\n\nExclusion Criteria:\n\n1. Central nervous system (CNS) metastases unless stable 2 months post definitive therapy with steroids.\n2. Unresolved AEs of Grade 2 or higher from prior anticancer therapy.\n3. Past or current history of autoimmune disease or immune deficiency.\n4. History of other malignancy within 3 years of first study treatment cycle.\n5. Current or recent treatment with certain therapies including specified anticancer treatments, modulators of CYP3A4 and immunomodulating therapies (prior treatment with CPIs is not exclusory).\n6. Known allergy or hypersensitivity to any of the test compounds, materials, or contraindication to test product.\n7. Clinically significant abnormal laboratory safety tests.",{"count":99,"type":21},90,[25],"This clinical study is testing whether a new combination of medicines (DSP107 and atezolizumab) is more effective and safer than an existing treatment (fruquintinib) for people with advanced colorectal cancer that is microsatellite stable (MSS). Participants will be randomly assigned to receive one of the two treatments, and researchers will monitor how well the cancer responds, how safe the treatments are, and how the body processes them. The study hopes to show that the new combination can improve outcomes for patients with this type of colorectal cancer.",[33],{"date":35,"type":38},{"date":105,"type":38},"2026-01-16",{"date":107,"type":21},"2027-04-30",{"name":109,"class":89},"Kahr Bio Australia Pty Ltd",18,{"id":112,"slug":113,"hasResults":12,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":4,"eligibilityCriteria":117,"healthyVolunteers":12,"sex":17,"minAge":118,"maxAge":4,"enrollmentInfo":119,"targetDuration":4,"studyType":22,"phases":121,"briefSummary":123,"conditions":124,"keywords":129,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":136,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":46},"100610399","dosing-physical-activity-among-older-cancer-survivors-who-experience-chronic-pain-a-micro-randomized-trial-100610399","NCT07227077","Dosing Physical Activity Among Older Cancer Survivors Who Experience Chronic Pain: a Micro-randomized Trial","An Adaptive Design for Dosing Physical Activity Among Older Cancer Survivors Who Experience Chronic Pain: a Micro-randomized Trial","Inclusion Criteria:\n\n1. Age greater than or equal to 65 years.\n2. Patients with a history of bladder, breast, cervical, colorectal, endometrial, lung, and prostate cancer diagnosis and treatment.\n3. Fluent in spoken and written English.\n4. Patient has access to smartphone\n5. Ability to understand a written informed consent document, and the willingness to sign it.\n\nExclusion Criteria:\n\n1. Patient has metastatic disease.\n2. Patient has cancer recurrence.","65 Years",{"count":120,"type":21},50,[122],"NA","The purpose of this study is to assess the best time to deliver a message to increase physical activity and how often participants will experience a pain episode in the 24 hours following their receipt of a message to increase physical activity.",[125,66,126,33,65,127,128],"Breast Cancer","Bladder Cancer","Lung Cancer","Prostate Cancer",[130,131,132,133,134,135],"Physical Activity","Exercise","Survivorship","Supportive Care","Pain","Symptom Management",{"date":35,"type":38},{"date":138,"type":38},"2026-02-07",{"date":140,"type":21},"2027-05-01",{"name":142,"class":45},"Medical College of Wisconsin",{"id":144,"slug":145,"hasResults":12,"nctId":146,"briefTitle":147,"officialTitle":148,"acronym":149,"eligibilityCriteria":150,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":151,"targetDuration":153,"studyType":154,"phases":4,"briefSummary":155,"conditions":156,"keywords":161,"overallStatus":171,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":4},"100652712","nomad-gi-molecular-guided-non-operative-management-and-organ-preservation-strategy-after-precision-therapy-in-gastrointestinal-cancers-100652712","NCT07775859","NOMAD-GI: Molecular-guided Non-operative Management and Organ Preservation Strategy After Precision Therapy in Gastrointestinal Cancers","Safety and Efficacy of Molecular-guided Non-operative Management and Organ Preservation Strategy After Precision Therapy in Gastrointestinal Cancers: A Single-center Bidirectional Cohort Study","NOMAD-GI","Inclusion Criteria:\n\n1. Adults aged 18 years or older at the time of study enrollment.\n2. Histologically confirmed gastrointestinal malignancy, including gastric cancer, gastroesophageal junction cancer, esophageal cancer, or colorectal cancer.\n3. Presence of at least one molecular biomarker that may support selection of precision therapy, including but not limited to:\n\n   * Mismatch repair deficiency or microsatellite instability-high (dMMR\u002FMSI-H);\n   * Pathogenic or likely pathogenic POLE or POLD1 mutation;\n   * High programmed death ligand 1 combined positive score (PD-L1 CPS), when applicable to the tumor type and treatment strategy;\n   * Tumor mutational burden-high (TMB-H);\n   * Epstein-Barr virus-positive status (EBV-positive), when applicable;\n   * Human epidermal growth factor receptor 2 (HER2) positivity;\n   * Claudin 18.2 (CLDN18.2) positivity;\n   * Fibroblast growth factor receptor 2 (FGFR2) alteration;\n   * Mesenchymal-epithelial transition factor (MET) amplification or other actionable MET alteration;\n   * Neurotrophic tyrosine receptor kinase (NTRK) gene fusion;\n   * Kirsten rat sarcoma viral oncogene homolog G12C (KRAS G12C) mutation;\n   * Other clinically actionable molecular alterations recognized according to contemporary clinical practice.\n4. Receipt of molecular biomarker-guided precision therapy before assessment for non-operative management or organ-preservation strategy. Precision therapy may include immune checkpoint inhibitor therapy, targeted therapy, or a combination of systemic therapies according to the participant's tumor type, molecular profile, clinical stage, and standard clinical practice.\n5. After completion or adequate exposure to precision therapy, achievement of a favorable clinical response that may support consideration of non-operative management or organ-preservation strategy, including clinical complete response (cCR), near-complete response (near-cCR), major tumor regression, or other predefined favorable response categories.\n6. Multidisciplinary team (MDT) evaluation has been performed to determine whether non-operative management, local treatment, organ-preservation strategy, or radical surgery is appropriate.\n7. Adequate clinical information is available for assessment of treatment response, including appropriate imaging, endoscopic evaluation, pathological evaluation, or other clinically indicated examinations.\n8. Ability and willingness to comply with the predefined surveillance and follow-up schedule.\n9. For the prospective cohort, written informed consent is obtained before enrollment and study-specific data collection.\n10. For the retrospective cohort, eligible clinical data are available in the institutional medical records and may be used according to institutional ethics approval and applicable regulations.\n\nExclusion Criteria:\n\n1. Uncontrolled progressive metastatic disease or clinical deterioration that precludes evaluation for the study treatment strategy.\n2. Patients who are unable to undergo appropriate clinical, radiological, endoscopic, or pathological assessment required for response evaluation or follow-up.\n3. Previous treatment history or concurrent medical conditions that, in the judgment of the multidisciplinary team, preclude reliable assessment of tumor response or implementation of the predefined surveillance strategy.\n4. Severe comorbidities or medical conditions that make continued follow-up or additional treatment evaluation clinically inappropriate.\n5. Inability or unwillingness to comply with the predefined follow-up schedule.\n6. Withdrawal of informed consent for prospective participants.\n7. Insufficient clinical information to determine eligibility, treatment response, treatment strategy, or follow-up outcomes.\n8. Patients with conditions that require immediate radical surgery or other urgent treatment according to multidisciplinary clinical assessment and who cannot safely undergo the predefined study evaluation.",{"count":152,"type":21},200,"3 Months","OBSERVATIONAL","The NOMAD-GI study is a single-center, bidirectional cohort study designed to evaluate the safety and efficacy of molecular biomarker-guided non-operative management (NOM) and organ preservation strategies after precision therapy in patients with gastrointestinal cancers.\n\nPatients with actionable molecular biomarkers, including dMMR\u002FMSI-H, POLE mutation, PD-L1 high expression, tumor mutational burden-high (TMB-H), Epstein-Barr virus positivity (EBV+), HER2 positivity, CLDN18.2 positivity, and other actionable genomic alterations, will be enrolled.\n\nAfter immune checkpoint inhibitor or targeted therapy, patients achieving favorable clinical responses will undergo multidisciplinary team (MDT) evaluation and receive either non-operative management, local treatment, or radical surgery according to individualized treatment decisions.\n\nThe study aims to establish a molecular-driven organ preservation paradigm for gastrointestinal cancers and evaluate whether NOM can provide comparable oncological outcomes while improving functional outcomes and quality of life.",[157,158,159,160,33],"Gastrointestinal Cancer","Gastric Cancer","Gastroesophageal Junction Cancer","Esophageal Cancer",[162,163,164,165,166,167,168,169,170],"Precision oncology","Molecular biomarkers","Gastrointestinal cancer","Non-operative management","Organ preservation","Immunotherapy","Targeted therapy","Watch and wait","Multidisciplinary treatment","NOT_YET_RECRUITING","2026-08-18",{"date":35,"type":38},{"date":175,"type":21},"2026-09-01",{"date":177,"type":21},"2031-09-01",{"name":179,"class":45},"Peking University Cancer Hospital & Institute",{"id":181,"slug":182,"hasResults":12,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":4,"eligibilityCriteria":186,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":187,"enrollmentInfo":188,"targetDuration":4,"studyType":22,"phases":190,"briefSummary":191,"conditions":192,"keywords":193,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":196,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":46},"100637262","histidine-supplementation-for-antitumor-immunity-in-colorectal-cancer-100637262","NCT07577505","Histidine Supplementation for Antitumor Immunity in Colorectal Cancer","A Single-arm Clinical Study of Histidine Supplementation for Antitumor Immunity in Colorectal Cancer","Inclusion Criteria:\n\n1. Patients aged 18-80 years, regardless of sex.\n2. Body mass index (BMI) ≥18.5.\n3. NRS-2002 score \\\u003C3.\n4. Diagnosed with stage II or higher colorectal cancer who require pharmacological intervention.\n5. Capable of oral intake of medication.\n6. Willing to participate in the study and provide written informed consent.\n\nExclusion Criteria:\n\n1. Participation in other interventional clinical trials (including drugs, nutritional supplements, medical devices, etc.) within 4 weeks prior to enrollment.\n2. Presence of ascites, severe diarrhea, intractable vomiting, severe malabsorption syndrome, paralysis, mechanical intestinal obstruction, or active gastrointestinal bleeding.\n3. Allergy to sample components.\n4. Current use of other nutritional supplements that may affect the validity and effectiveness of the study results.\n5. Pregnant, lactating female patients or women with fertility who test positive in the baseline pregnancy test.\n6. Presence of cognitive impairments or mental illnesses that prevent understanding of the study procedures.\n7. Presence of any other conditions, judged by the researcher, make the participant unsuitable for participation in the study.","80 Years",{"count":189,"type":21},20,[122],"The goal of this clinical study is to learn whether oral histidine supplementation may be safely used to support antitumor immune function during standard colorectal cancer treatment.\n\nParticipants with colorectal cancer in the supplementation group will:\n\nTake 2g oral histidine once daily during standard colorectal cancer treatment; Provide blood samples before and after supplementation; Attend regular follow-up visits for laboratory tests, safety assessment, and treatment evaluation.",[33],[33,194,195],"Histidine","Immune functions",{"date":35,"type":38},{"date":198,"type":38},"2026-05-06",{"date":200,"type":21},"2027-06",{"name":202,"class":45},"Jing-yuan Fang, MD, Ph. D",{"id":204,"slug":205,"hasResults":12,"nctId":206,"briefTitle":207,"officialTitle":208,"acronym":4,"eligibilityCriteria":209,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":210,"targetDuration":4,"studyType":22,"phases":212,"briefSummary":213,"conditions":214,"keywords":216,"overallStatus":171,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":46},"100609835","transanal-irrigation-for-the-management-of-early-low-anterior-resection-syndrome-lars-100609835","NCT07219745","Transanal Irrigation for the Management of Early Low Anterior Resection Syndrome (LARS)","Transanal Irrigation for the Management of Early Low Anterior Resection Syndrome (LARS): A Pilot Randomized Controlled Trial","Inclusion Criteria:\n\n1. Adults (≥18 years-old) patients who underwent a LAR for any indication via open, laparoscopic, robotic, or transanal total mesorectal excision, with creation of a diverting loop ileostomy,\n2. have confirmed anastomotic healing demonstrated by flexible sigmoidoscopy and CT scan with rectally-administered water soluble contrast or gastrograffin enema,\n3. are planned for an ileostomy closure operation, and\n4. are in the first 12 months post-LAR operation\n\nExclusion Criteria:\n\n1. Inability to comprehend English or Spanish or provide informed consent (Note: after the English documents are approved, the study team plans to obtain a Spanish consent and study documents),\n2. ongoing chemotherapy or radiotherapy, and\n3. ongoing anastomotic complication.",{"count":211,"type":21},60,[122],"Transanal irrigation (TAI) has shown to improve fecal incontinence and increase quality of life in patients with low anterior resection syndrome (LARS). This trial is a small study being conducted to determine whether a larger trial is feasible. Investigators are also doing this research to see if TAI impacts quality of life and improves bowel function within the early post-operative period (1-12 months).\n\nThis treatment is designed for participants to have more control over their bowel movements and reduce the dependency on immediate access to the toilet.",[33,215],"Low Anterior Resection Syndrome",[217,218,215,219],"Transanal irrigation","Peristeen Transanal Irrigation System","LARS","2026-08-17",{"date":172,"type":38},{"date":223,"type":21},"2026-10",{"date":225,"type":21},"2027-11",{"name":227,"class":45},"Case Comprehensive Cancer Center",{"id":229,"slug":230,"hasResults":12,"nctId":231,"briefTitle":232,"officialTitle":232,"acronym":4,"eligibilityCriteria":233,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":234,"enrollmentInfo":235,"targetDuration":4,"studyType":22,"phases":237,"briefSummary":238,"conditions":239,"keywords":242,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":244,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":249,"locationsCount":46},"100531621","exercise-for-gut-microbiome-in-patients-with-young-onset-colorectal-cancer-undergoing-chemotherapy-the-courage-trial-100531621","NCT06202183","Exercise for Gut Microbiome in Patients With Young-Onset Colorectal Cancer Undergoing Chemotherapy: The COURAGE Trial","Inclusion Criteria:\n\n* Patient diagnosed with early-stage or metastatic colon or rectal cancer\n* Age at diagnosis 18-50 years; due to the specificity of the study question those outside the age bracket will not be included\n* No plans for major surgical intervention at the time of recruitment for a minimum of 12 weeks (i.e. study period; placement of port a cath is allowed)\n* No plans for radiation therapy at the time of recruitment for a minimum of 12 weeks\n* On or planning chemotherapy\n* Participate in less than or equal to 90 minutes of moderate-to-vigorous exercise per week\n* Medical clearance to perform exercise intervention and testing by their treating oncologist\n* No uncontrolled medical conditions that could be exacerbated with exercise\n* Ability to communicate and complete written forms in English\n* Ability to understand and the willingness to sign informed consent prior to any study-related procedures\n* Willing to travel to DFCI for necessary data collection\n\nExclusion Criteria:\n\n* Participate in more than 90 minutes of moderate-to-vigorous aerobic exercise per week over the past month. This study targets insufficiently active persons to assess the effect of the described exercise intervention, where additional exercise done regularly will contaminate the intervention effects.\n* Unstable comorbidities that prevent participation in moderate-to-vigorous intensity exercise. Patients with unstable comorbidities may develop unexpected adverse events from exercise. For the purpose of patients' safety, as well as because this study involves remote, home-based exercise where close supervision is not possible, patients with unstable medical conditions are excluded.\n* Patients actively on a weigh loss diet and\u002For actively taking weight loss drugs. This could effect gut microbiome.\n* Patient with other active malignancies (excluding basal cell carcinoma).\n* Subjects who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study.","50 Years",{"count":236,"type":21},84,[122],"This research study is a randomized controlled trial that will observe changes in microbiome activity, changes in chemotherapy toxicity, and any changes in treatment outcomes between two groups of participants undergoing chemotherapy with either early-stage or metastatic colorectal cancer.\n\nThe names of the study groups involved in this study are:\n\n* Exercise\n* Waitlist Control",[33,240,241],"Metastatic Colon Cancer","Metastatic Colorectal Cancer",[33,240,241,243],"Early Stage Colorectal Cancer",{"date":81,"type":38},{"date":246,"type":38},"2024-07-22",{"date":248,"type":21},"2028-07-31",{"name":250,"class":45},"Dana-Farber Cancer Institute",{"id":252,"slug":253,"hasResults":12,"nctId":254,"briefTitle":255,"officialTitle":255,"acronym":4,"eligibilityCriteria":256,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":257,"targetDuration":4,"studyType":154,"phases":4,"briefSummary":259,"conditions":260,"keywords":263,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":267,"lastUpdatePostDateStruct":268,"startDateStruct":269,"completionDateStruct":4,"leadSponsor":271,"locationsCount":46},"100054764","evaluation-for-nci-surgery-branch-clinical-research-protocols-100054764","NCT00001823","Evaluation for NCI Surgery Branch Clinical Research Protocols","* INCLUSION CRITERIA:\n\nAge \\>= 18 years.\n\nPatient suspected of having, or with biopsy proven, malignant disease.\n\nPatient is able to understand and willing to sign a written informed consent document.\n\nPatient is being evaluated for treatment on an NCI-SB protocols.\n\nEXCLUSION CRITERIA:\n\nWomen of child-bearing potential who are pregnant or plan to become pregnant because of the potentially dangerous effects of some of the screening procedures (e.g., nuclear medicine or other imaging scans) on the fetus.",{"count":258,"type":21},7000,"Background:\n\nThe National Cancer Institute Surgery Branch (NCI-SB) has developed experimental therapies that involve taking white blood cells from patients' tumor or from their blood, growing them in the laboratory in large numbers, and then giving the cells back to the patient.\n\nObjective:\n\nThis study will allow patients to under screening and evaluation for participation in NC-SB Protocols.\n\nEligibility:\n\nPatients 18 years or older must meet the minimum eligibility criteria for an NCI-SB treatment protocol.\n\nDesign\n\nPatients will undergo testing and evaluations as required by the appropriate NCI-SB treatment protocol.\n\n...",[261,262,33,127,126],"Synovial Cell Cancer","Melanoma",[264,265,167,266],"Cancer","Gene Therapy","Clinical Trial","2026-08-15",{"date":172,"type":38},{"date":270,"type":38},"1999-07-11",{"name":272,"class":273},"National Cancer Institute (NCI)","NIH",{"id":275,"slug":276,"hasResults":12,"nctId":277,"briefTitle":278,"officialTitle":279,"acronym":280,"eligibilityCriteria":281,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":282,"targetDuration":4,"studyType":22,"phases":284,"briefSummary":285,"conditions":286,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":289,"lastUpdatePostDateStruct":290,"startDateStruct":291,"completionDateStruct":293,"leadSponsor":295,"locationsCount":90},"100634856","phase-1-a-phase-1a1b-first-time-in-human-study-of-ct-202-a-nectin-4-directed-bispecific-antibody-in-participants-with-recurring-triple-negative-breast-colorectal-urothelial-cancers-100634856","NCT07545122","A Phase 1a\u002F1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, Urothelial Cancers","A Phase 1a\u002F1b, First Time in Human Study of CT-202, A Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, and Urothelial Cancers","CT-202","Inclusion Criteria:\n\n* Participants with nectin-4-positive triple negative breast cancer, colorectal cancer, or urothelial cancer that have received standard therapies\n* Participants with measurable disease per RECIST 1.1\n* ECOG 0, 1, or 2 and life expectancy of ≥ 12 weeks\n* Participants have adequate organ function.\n\nExclusion Criteria:\n\n* History of severe skin toxicity\n* Uncontrolled significant active infection or any medical or other condition that in the opinion of the Investigator would preclude the participant's participation in the study.\n* Concurrent participation in another investigational clinical trial.",{"count":283,"type":21},162,[24],"This is a Phase 1a\u002F1b, first time in human (FTIH), open-label, dose escalation and expansion study to evaluate the safety, tolerability, and preliminary efficacy of CT-202 (study drug), a humanized T cell engaging bispecific antibody targeting nectin-4, in participants with nectin-4 expressing recurrent, unresectable or metastatic refractory\u002Fresistant TNBC, CRC, or UC. Results of the study including PK, PD, efficacy, and safety will be used in the RP2D determination.",[287,33,288],"Triple Negative Breast Cancer (TNBC)","Urothelial Cancer","2026-08-14",{"date":172,"type":38},{"date":292,"type":21},"2026-09",{"date":294,"type":21},"2030-01",{"name":296,"class":89},"Context Therapeutics Inc.",{"id":298,"slug":299,"hasResults":12,"nctId":300,"briefTitle":301,"officialTitle":302,"acronym":4,"eligibilityCriteria":303,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":304,"targetDuration":4,"studyType":22,"phases":306,"briefSummary":307,"conditions":308,"keywords":309,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":289,"lastUpdatePostDateStruct":310,"startDateStruct":311,"completionDateStruct":313,"leadSponsor":315,"locationsCount":317},"100572039","phase-2-addition-of-antibiotics-to-upfront-treatment-regimen-for-colorectal-cancer-100572039","NCT06728072","Addition of Antibiotics to Upfront Treatment Regimen for Colorectal Cancer","Pilot Study Evaluating Microbiome Modulation Therapy (MBMT) With Ciprofloxacin, Metronidazole, and Aspirin in Addition to Standard of Care Chemotherapy in Patients Undergoing First-Line Therapy for Metastatic Colorectal Cancer","Inclusion Criteria:\n\n* Diagnosis of stage IV colorectal cancer\n* Measurable disease by Response evaluation criteria in solid tumors (RECIST) 1.1 criteria\n* Planned first-line treatment with a 5FU-based doublet chemotherapy regimen for colon cancer, specifics of the regimen at the discretion of the treating physician Note: Patients who have received adjuvant therapy \\>6 months prior are eligible\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2\n* Absolute neutrophil count (ANC) ≥1,500 cells\u002FμL\n* Platelet count ≥100,000 cells\u002FμL\n* Hemoglobin ≥8 g\u002FdL Note: The use of transfusion or other intervention to achieve hemoglobin ≥8 g\u002FdL is acceptable.\n* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 × upper limit of normal (ULN) Note: Patients with documented liver metastases: AST and ALT ≤5 × ULN\n* Serum creatinine ≤1.5 x ULN or calculated creatinine clearance ≥40 mL\u002Fmin using the Cockcroft-Gault equation: (140 - age) × body weight\u002Fplasma creatinine × 72 (× 0.85 if female)\n* Radiographically measurable disease by RECIST 1.1\n* Nonpregnant and not actively breastfeeding\n* Sexually active patients of childbearing potential and their partners must agree to use medically acceptable form of contraception, per treating investigator, throughout the study Patients should continue to use medically acceptable methods of contraception after study treatment ends, following the guidance for their specific chemotherapy regimen.\n\nChildbearing potential excludes:\n\nAge \\> 50 years and naturally amenorrhoeic for \\> 1 year OR previous hysterectomy or bilateral salpingo-oophorectomy\n\n* Patients on a pre-existing daily aspirin regimen may participate in the study without interrupting this regimen.\n* Patients with a contraindication to aspirin may participate in the study. These patients will not be required to take aspirin as part of the study treatment.\n\nExclusion Criteria:\n\n* Total colectomy\n* Diagnosed with Cockayne Syndrome\n* Using disulfiram, tizanidine, or theophylline and unable to stop taking these medications for the length of the microbiome modulation therapy\n* On methotrexate doses of 15 mg\u002Fweek or more\n* History of allergic reaction to ciprofloxacin, metronidazole, or aspirin\n* Fuss course of antibiotics in the 30 days before chemotherapy start Note: Full course is defined as ≥5 doses with an intent to treat a defined infection. Use of antibiotics intended for prophylaxis at the time of surgery is allowed\n* Corrected QT interval (QTc) \\>480 on baseline ECG\n* Diagnosed with a malabsorptive syndrome\n* Inability to swallow tablets",{"count":305,"type":21},97,[25],"This is a 2-arm, noncomparative phase 2 trial designed to evaluate treatment outcomes with or without the addition of ciprofloxacin, metronidazole, and aspirin to first-line chemotherapy for patients with stage IV colorectal cancer (CRC).",[33,76],[33,76],{"date":172,"type":38},{"date":312,"type":38},"2025-03-07",{"date":314,"type":21},"2035-07-01",{"name":316,"class":45},"Virginia Commonwealth University",2,{"id":319,"slug":320,"hasResults":12,"nctId":321,"briefTitle":322,"officialTitle":323,"acronym":4,"eligibilityCriteria":324,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":325,"targetDuration":4,"studyType":154,"phases":4,"briefSummary":327,"conditions":328,"keywords":332,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":289,"lastUpdatePostDateStruct":334,"startDateStruct":335,"completionDateStruct":337,"leadSponsor":339,"locationsCount":46},"100538206","french-assessment-of-mrd-by-liquid-biopsies-in-stage-iii-crc-patients-frenchmrdcrc-100538206","NCT06287814","French Assessment of MRD by Liquid Biopsies in Stage III CRC Patients (FRENCH.MRD.CRC)","French Assessment of Minimal Residual Disease by Liquid Biopsies in Stage III Colorectal Patients","FRENCH.MRD.CRC PART I Inclusion criteria\n\n* Colon or rectal cancer, clinical tumor stage I-III.\n* Patient 18 years or older.\n* Scheduled for curative intent resection surgery (including \"compromised\" curative resections).\n\nExclusion criteria\n\n* Hereditary colorectal cancer linked to familial colonic polyposis or Lynch syndrome.\n* Verified distant metastases.\n* Malignant colorectal polyps diagnosed after polypectomy.\n* Patients who are unlikely to comply with the protocol (e.g. uncooperative attitude), inability to return for subsequent visits) and\u002For otherwise considered by the Investigator to be unlikely to complete the study.\n* Pregnant or nursing woman, or in childbearing age and not willing to use contraception\n* Protected and vulnerable adult\n* Not covered by Health insurance\n* Patient unable to understand and sign written informed consent.\n\nFRENCH.MRD.CRC PART II Inclusion criteria\n\n* Participation in FRENCH.MRD.CRC part 1 - SURGERY\n* Colorectal cancer, UICC stage III\n* Has received curative-intent resection and is a candidate for adjuvant chemotherapy (3- or 6-months regime) Exclusion criteria\n* Inflammatory bowel disease (Crohn's disease or ulcerative colitis) related colon cancer\n* Not treated with adjuvant chemotherapy despite indication (incomplete treatment not included)\n* Treated with neoadjuvant chemo-radiation therapy\n* Synchronous colorectal and non-colorectal cancer diagnosed per operative (except skin cancer other than melanoma)\n* Other cancers (excluding colorectal cancer or skin cancer other than melanoma) within 3 years from eligibility screening\n* Patients who are unlikely to comply with the protocol (e.g. uncooperative attitude), inability to return for subsequent visits) and\u002For otherwise considered by the Investigator to be unlikely to complete the study",{"count":326,"type":21},70,"Improving personalized cancer treatments and finding the best strategies to treat each patient relies on using new diagnostic technologies. Currently, for colorectal cancer, the methods used to decide who gets additional post-surgery treatment are suboptimal. Some patients get too much treatment, while others do not get enough.\n\nThere is a new way to explore if there is any cancer left in a patient's body using circulating tumor DNA (ctDNA) detected in blood samples. This can help decide who needs more treatment after surgery. Even though many tests have been developed, it has yet to be determined which test performs best at relevant time points.\n\nThe GUIDE.MRD consortium is a group of experts, including scientists, technology, and pharmaceutical companies. The consortium is working on creating a reliable standard for the ctDNA tests, validating their clinical utility, and collecting data to help decide on the best treatment for each patient.\n\nFRENCH-MRD-CRC is the French study of the european GUIDE.MRD project.",[33,329,330,331],"Stage III Colon Cancer","Minimal Residual Disease","Liquid Biopsy",[333,330,331],"Stage III colorectal cancer",{"date":172,"type":38},{"date":336,"type":38},"2024-04-11",{"date":338,"type":21},"2033-10-31",{"name":340,"class":45},"University Hospital, Montpellier",{"id":342,"slug":343,"hasResults":12,"nctId":344,"briefTitle":345,"officialTitle":346,"acronym":4,"eligibilityCriteria":347,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":348,"targetDuration":4,"studyType":22,"phases":350,"briefSummary":352,"conditions":353,"keywords":4,"overallStatus":171,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":355,"startDateStruct":356,"completionDateStruct":358,"leadSponsor":360,"locationsCount":4},"100652543","phase-3-study-of-petosemtamab-plus-chemotherapy-versus-cetuximab-or-bevacizumab-plus-chemotherapy-in-ras-and-braf-wild-type-recurrent-unresectable-or-metastatic-colorectal-cancer-liger-crc2-100652543","NCT07775287","Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2)","A Randomized, Open-label, Phase 3 Trial of Petosemtamab + FOLFIRI\u002FmFOLFOX6 Versus Cetuximab or Bevacizumab + FOLFIRI\u002FmFOLFOX6 as Second-line Treatment in Participants With RAS and BRAF Wild-type, Recurrent, Unresectable or Metastatic Colorectal Cancer","Key Inclusion Criteria:\n\n* Histologically or cytologically confirmed colorectal adenocarcinoma that is recurrent, unresectable or metastatic.\n* Must have documented KRAS and NRAS wt CRC, as determined by medical record of results from local testing or as assessed by central testing. Next-generation sequencing-based test results from tumor tissue are required for determining eligibility. At a minimum, local testing must have assessed the mutational status of KRAS and NRAS G12\u002FG13, A59, Q61, K117, and A146 codons.\n* Has received no more than 1 line of prior systemic therapy for unresectable or metastatic CRC, with documented disease progression. First line (1L) regimen must be fluoropyrimidine- and oxaliplatin- (if 2L choice of backbone is FOLFIRI) or irinotecan- (if 2L choice of backbone is fluorouracil + leucovorin (calcium folinate) + oxaliplatin \\[FOLFOX\\]) based. Prior anti-vascular endothelial growth factor receptor (VEGF) treatment is allowed.\n* Must be eligible for treatment with mFOLFOX6 (if assigned by the investigator to receive mFOLFOX6) or FOLFIRI (if assigned by the investigator to receive FOLFIRI) according to local regulatory approvals and standard of care (SOC) guidelines.\n\nKey Exclusion Criteria:\n\n* BRAF V600 mutation (eg, V600E) and\u002For microsatellite instability-high\u002Fdeficient mismatch repair tumor status and\u002For ERBB2\u002Fhuman epidermal growth factor receptor 2 (HER2) positive\u002Famplified tumor status as documented by local test results in the medical record or from central testing or known documented activating HRAS mutation identified prior to enrollment from local testing results in the medical record, if available .\n* Prior exposure to any agents that target epidermal growth factor receptor (EGFR) (including but not limited to protein products, monoclonal antibodies, tyrosine kinase inhibitors, or antisense oligonucleotide therapy).\n* Prior exposure to irinotecan (for participants assigned to FOLFIRI) or oxaliplatin (for participants assigned to FOLFOX) in the metastatic setting.\n* Known complete dihydropyrimidine dehydrogenase (DPD) deficiency or known homozygous\u002Fcompound heterozygous dihydropyrimidine dehydrogenase gene (DPYD) variants associated with complete loss of DPD activity. Testing for DPD deficiency should be performed per local guidelines.\n* For a participant who is to receive FOLFIRI: known to be homozygous for the uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1)\\*28 or \\*6 alleles or compound or double heterozygous for the UGT1A1\\*28 and \\*6 alleles. Testing for UGT1A1 should be done in accordance with local guidelines.\n* Participants with non-colorectal adenocarcinumatous disease.\n\nNote: Other protocol-defined Inclusion and Exclusion criteria may apply.",{"count":349,"type":21},600,[351],"PHASE3","The purpose of this trial is to evaluate how well petosemtamab in combination with chemotherapy works against colorectal cancer that has recurred after previous treatment and that cannot be safely removed by surgery or has spread to other parts of the body.\n\nParticipants will receive either petosemtamab + doctor's choice of chemotherapy (mFOLFOX6 or FOLFIRI) or doctor's choice of standard-of-care (SOC) cetuximab or bevacizumab + chemotherapy (mFOLFOX6 or FOLFIRI). No participants will be given placebo.\n\nThe treatment duration will be different for every participant. If a participant's cancer stays the same or gets better, and there are not any serious problems, participants can keep getting study treatment for as long as the study is open.\n\nParticipants will be asked to attend 2 visits at the study clinic for each cycle (duration of cycle is 4 weeks). During visits, there will be various tests (such as blood draws) and procedures (such as imaging) to monitor whether the study treatment is safe and effective.\n\nThe overall study duration (including screening, treatment, and follow-up) will be different for every participant.",[33],"2026-08-13",{"date":35,"type":38},{"date":357,"type":21},"2026-09-15",{"date":359,"type":21},"2030-01-31",{"name":361,"class":89},"Genmab",{"id":363,"slug":364,"hasResults":12,"nctId":365,"briefTitle":366,"officialTitle":366,"acronym":367,"eligibilityCriteria":368,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":369,"targetDuration":4,"studyType":22,"phases":371,"briefSummary":372,"conditions":373,"keywords":4,"overallStatus":171,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":375,"startDateStruct":376,"completionDateStruct":378,"leadSponsor":380,"locationsCount":46},"100611610","reducing-neoplasia-recurrence-after-non-thermal-endoscopic-resection-of-large-colorectal-polyps-100611610","NCT07242820","Reducing Neoplasia Recurrence After Non-thermal Endoscopic Resection of Large Colorectal Polyps","COSA-RCT","Inclusion Criteria:\n\n* Adult patients\n* Undergoing EMR for large (≥20 mm) colorectal LSL\n* Providing written and informed consent for study participation\n\nExclusion Criteria:\n\n* Inflammatory bowel disease\n* Non-elective colonoscopy\n* Poor general health (American Society of Anesthesiologists classification \\>III)\n* Coagulopathy or thrombocytopenia (international normalized ration ≥1.5 or platelets \\\u003C50\\*10\\^9\u002FL)\n* Bulky lesions (granular mixed with ≥10mm module).",{"count":370,"type":21},752,[122],"The goal of this clinical trial is to clarify the role of adjuvant thermal ablation for non-thermal endoscopic mucosal resection (EMR) of large (≥20mm) flat colorectal polyps (so-called laterally spreading lesions \\[LSLs\\]).\n\nThe hypothesis is that adding adjuvant thermal ablation to non-thermal EMR (vs no ablation) will result in lower lesion recurrence rates at 6-month follow-up, and non-inferior adverse events (AE) rates 14 days post EMR.\n\nFor participants with planned EMR, endoscopists will perform non-thermal EMRs as per standard of care and:\n\n* adjuvant thermal ablation will either not be performed (control group), or will be applied to the base and outside margins of the resection site (experimental group);\n* then, all patients will be contacted 14-44 days after EMR, to verbally ascertain the occurrence of AEs;\n* then, all patients will undergo a first follow-up colonoscopy at 6 months after initial conoloscopy to assess lesion recurrence;\n* finally, all patients will undergo a second and final colonoscopy 18 months after EMR.",[33,374],"Polyp of Colon",{"date":289,"type":38},{"date":377,"type":21},"2026-12",{"date":379,"type":21},"2032-05",{"name":381,"class":45},"Centre hospitalier de l'Université de Montréal (CHUM)",{"id":383,"slug":384,"hasResults":12,"nctId":385,"briefTitle":386,"officialTitle":387,"acronym":4,"eligibilityCriteria":388,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":389,"targetDuration":4,"studyType":22,"phases":391,"briefSummary":392,"conditions":393,"keywords":395,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":400,"startDateStruct":401,"completionDateStruct":403,"leadSponsor":405,"locationsCount":407},"100516417","phase-1-a-study-to-evaluate-the-safety-pharmacokinetics-and-anti-tumor-activity-of-vvd-133214-as-monotherapy-and-in-combination-in-participants-with-advanced-solid-tumors-100516417","NCT06004245","A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors","A Phase I, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors Harboring Microsatellite Instability (MSI) and\u002For Deficient Mismatch Repair (dMMR)","Inclusion Criteria:\n\n* Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1\n* Have a microsatellite instability (MSI) and\u002For deficient mismatch repair (dMMR), histologically or cytologically documented advanced (unresectable and\u002For metastatic) solid tumor; For the combination with bevacizumab only: advanced, or metastatic colorectal adenocarcinoma (CRC) treated with at least 2 but no more than 3 prior lines of systemic therapy for the treatment of advanced CRC; For the combination with pembrolizumab only: Histologically confirmed locally advanced, or metastatic CRC with no prior systemic treatment for metastatic disease and not amenable to surgery\n* Have received and then progressed following, or are intolerant to, standard therapy in the advanced setting\n* Presence of measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1\n* Life expectancy of at least (≥)12 weeks\n* Availability of formaldehyde-fixed paraffin-embedded (FFPE) archival tumor tissue for submission to Sponsor\u002Fcentral laboratory for retrospective central testing; for participants without archival tissue, a biopsy from either primary or metastatic tumor lesion, deemed medically feasible, must be taken\n* Adequate hematologic, end-organ, and cardiovascular function, as defined in the protocol\n\nExclusion Criteria:\n\n* Inability or unwillingness to swallow pills\n* Malabsorption syndrome or other condition that would interfere with enteral absorption\n* Known hypersensitivity or intolerance to ingredients from the study drug formulation including patients with rare genetic disorders such as galactosaemia, glucose-galactose intolerance or congenital lactase deficiency\n* Known uncontrolled central nervous system (CNS) metastases (progressing or requiring anticonvulsants or corticosteroids for symptomatic control) and\u002For carcinomatous meningitis\n* Known active or uncontrolled bacterial, viral, fungal, mycobacterial (including but not limited to tuberculosis and atypical mycobacterial disease), parasitic, or other infection (excluding fungal infections of nail beds), or any major episode of infection requiring treatment with intravenous antibiotics or hospitalization within 2 weeks prior to the start of drug administration (related to the completion of the course of antibiotics, except if for tumor fever) or 6 months for any intracranial abscess\n* Has a positive test at screening for hepatitis B virus, hepatitis C virus, or for human immodeficiency virus (HIV), per local diagnostic standard and in accordance with local laws and regulations\n* Uncontrolled diabetes or symptomatic hyperglycemia (i.e., well controlled defined as a screening hemoglobin A1c \\\u003C8% and no urinary ketoacidosis)\n* Significant cardiovascular\u002Fcerebrovascular disease within 6 months prior to Day 1 of study drug administration\n* Alcohol or drug dependence or abuse\n* Patients with known Werner (WRN) syndrome\n* Prior treatment with any WRN helicase inhibitor\n* Treatment with moderate or strong CYP3A4 inducers within 14 days prior to initiation of study treatment\n* Treatment with moderate or strong CYP3A4 or P-glycoprotein inhibitors within 14 days prior to initiation of study treatment\n* Pregnancy, breastfeeding, or intention of becoming pregnant during the study\n\nAdditional Exclusion Criteria for the Combination with Bevacizumab Only:\n\n* Had major surgery within 4 weeks prior to study drug administration\n* Deep venous thrombosis (DVT) or pulmonary embolism (PE) within 12 weeks prior to study drug administration\n* Known coagulopathy that increases the risk of bleeding\n* Patients with Grade 2+ proteinuria (exception: if 24-hour urinary protein is less than 1.0 gm\u002F24 hours)\n\nAdditional Exclusion Criteria for the Combination with Pembrolizumab Only:\n\n* Active or history of autoimmune disease or immune deficiency with some exceptions\n* History of interstitial lung disease or pneumonitis\n* Treatment with systemic immunosuppressive medication (such as corticosteroids) within 2 weeks prior to initiation of study treatment with some exceptions\n* Treatment with organ transplant\u002Fgraft tissue",{"count":390,"type":21},280,[24],"This is a first-in-human, Phase I, open-label, multicenter, dose-escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of VVD-133214 monotherapy, and in combination with bevacizumab or pembrolizumab, in participants with microsatellite instability (MSI) and\u002For deficient mismatch repair (dMMR) advanced solid tumors. VVD-133214 is an oral drug that acts on a protein called Werner (WRN), which may promote the growth of cancers that are MSI and\u002For dMMR. By acting on WRN, VVD-133214 may be able to block the growth of these types of cancer.",[394,33],"Advanced Solid Tumors",[396,397,398,399],"Deficient mismatch repair","dMMR","Microsatellite instability","MSI",{"date":220,"type":38},{"date":402,"type":38},"2024-01-25",{"date":404,"type":21},"2027-05-31",{"name":406,"class":89},"Vividion Therapeutics, Inc.",43,{"id":409,"slug":410,"hasResults":12,"nctId":411,"briefTitle":412,"officialTitle":413,"acronym":4,"eligibilityCriteria":414,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":415,"targetDuration":4,"studyType":22,"phases":417,"briefSummary":418,"conditions":419,"keywords":430,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":439,"startDateStruct":440,"completionDateStruct":442,"leadSponsor":444,"locationsCount":446},"100509886","phase-1-fog-001-in-locally-advanced-or-metastatic-solid-tumors-100509886","NCT05919264","FOG-001 in Locally Advanced or Metastatic Solid Tumors","A Phase 1\u002F2 Study of FOG-001 in Participants With Locally Advanced or Metastatic Solid Tumors","Inclusion Criteria:\n\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Adequate organ and marrow function.\n\nAdditional Inclusion Criteria for Dose Escalation Cohorts (Part 1a and Part 1g):\n\n* Diagnosis of treatment-refractory advanced\u002Fmetastatic solid tumor that is non-MSI-H or non-dMMR colorectal cancer (CRC) or any other solid tumor with documented WNT- pathway activating mutations (WPAMs).\n\nAdditional Inclusion Criteria for Dose Escalation Cohorts (Part 1b):\n\n* Diagnosis of treatment-refractory advanced\u002Fmetastatic non-MSI-H or non-dMMR CRC.\n* At least one lesion that is suitable for a core needle biopsy.\n\nAdditional Inclusion Criteria for Dose Escalation and Dose Expansion Cohorts (Part 1c and Part 2c):\n\n* Histologically, cytologically, or radiographically confirmed HCC with a documented WPAM (by local ctDNA or tumor NGS testing) in APC or CTNNB1\n\nAdditional Inclusion Criteria for Dose Escalation and Dose Expansion Cohorts (Part 1d, Part 1h, and Part 2d):\n\n* Desmoid tumor (aggressive fibromatosis)\n\nAdditional Inclusion Criteria for Dose Escalation and Dose Expansion Cohorts (Part 1f-1 and Part 2f-1) FOG-001 + FOLFOX + Bevacizumab:\n\n* Diagnosis of locally advanced or metastatic non-MSI-H or non-dMMR CRC\n* Participants with tumors known to be negative for APC LoF mutations or CTNNB1 GoF mutations (per NGS tests) are not eligible.\n* One dose of mFOLFOX6 with or without bevacizumab in the unresectable or metastatic setting prior to enrollment is allowed.\n\nAdditional Inclusion Criteria for Dose Escalation and Dose Expansion Cohorts (Part 1f-2 and Part 2f-2): FOG-001 + Nivolumab\n\n* Non-MSI-H or non-dMMR (by local testing) CRC with or without liver metastases.\n* MSI-H CRC or solid tumors that are WPAM and resistant to a-PD-1\u002FPD-L1\n* Participants with tumors known to be negative for APC LoF mutations or CTNNB1 GoF mutations (per NGS tests) are not eligible\n\nAdditional Inclusion Criteria for Dose Escalation and Dose Expansion Cohorts (Part 1f-3 and Part 2f-3): FOG-001 + Trifluridine\u002FTipiracil + Bevacizumab\n\n* Diagnosis of locally advanced or metastatic non-MSI-H or non-dMMR (by local testing) CRC\n* Participants with tumors known to be negative for APC LoF mutations or CTNNB1 GoF mutations (per NGS tests) are not eligible.\n\nMonotherapy Dose Optimization (Part 1i): FAP\n\n* Diagnosis of phenotypic classical FAP with a documented APC mutation\n* Post-colectomy \\>6 months prior to first dose of study drug administration with measurable duodenal polyp burden\n\nAdditional Inclusion Criteria for Dose Expansion Cohort (Part 2a):\n\n* Diagnosis of locally advanced or metastatic non-MSI-H or non-dMMR (by local testing) CRC\n\nAdditional Inclusion Criteria for Dose Expansion Cohort (Part 2b):\n\n* Diagnosis of advanced or metastatic solid tumors with a documented WPAM (by local testing) or equivalent evidence\n\nExclusion Criteria:\n\n* Known history of bone metastasis. Bone metastasis are allowed for patients with mCRPC. For participants with FAP, osteomas are allowed.\n* Evidence of vertebral compression fracture or non-traumatic bone fracture within the past 12 months and who are not receiving antiresorptive therapy.\n* Osteoporosis, which is defined as a T-score of ≤-2.5 at the lumbar spine (L1 - L4), left (or right) femoral neck or left (or right) total hip as determined by DXA scan.\n* Uncontrolled inflammatory bowel disease (i.e., ulcerative colitis or Crohn's disease)\n* Unstable\u002Finadequate cardiac function.\n* Has known meningeal carcinomatosis, leptomeningeal carcinomatosis, spinal cord compression, or symptomatic or unstable brain metastases.\n* Pregnant, lactating, or planning to become pregnant.\n* Complete colectomy within 6 months of the first dose of study drug administration.",{"count":416,"type":21},619,[24,25],"The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).",[264,33,60,420,421,422,75,423,424,425,426,427,128,428,429],"Locally Advanced Solid Tumor","Metastatic Cancer","WNT Pathway","Desmoid","Microsatellite Stable Colorectal Cancer","Metastatic Castration-resistant Prostate Cancer","Familial Adenomatous Polyposis (FAP)","Endometrial Carcinoma","Microsatellite Instability-High Colorectal Cancer","Adamantinomatous Craniopharyngioma",[264,60,420,421,431,432,433,423,434,435,436,437,438],"WNT Pathway Activating Mutation (WPAM)","Colorectal Cancer (CRC)","Microsatellite Stable (MSS)","Hepatocellular Carcinoma (HCC)","Adenomatous Polyposis Coli (APC)","β-catenin","Beta-catenin","CTNNB1",{"date":220,"type":38},{"date":441,"type":38},"2023-05-23",{"date":443,"type":21},"2027-08-31",{"name":445,"class":89},"Parabilis Medicines, Inc.",33,{"id":448,"slug":449,"hasResults":12,"nctId":450,"briefTitle":451,"officialTitle":452,"acronym":4,"eligibilityCriteria":453,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":454,"targetDuration":4,"studyType":22,"phases":456,"briefSummary":458,"conditions":459,"keywords":464,"overallStatus":171,"whyStopped":4,"lastUpdateSubmitDate":466,"lastUpdatePostDateStruct":467,"startDateStruct":468,"completionDateStruct":470,"leadSponsor":472,"locationsCount":4},"100652042","phase-4-tucatinib-continuation-study-100652042","NCT07768358","Tucatinib Continuation Study","TUCATINIB CONTINUATION PROTOCOL: AN OPEN-LABEL STUDY FOR PARTICIPANTS FROM TUCATINIB CLINICAL STUDIES","Inclusion Criteria:\n\n1. Be receiving tucatinib as a study intervention and deriving clinical benefit without evidence of disease progression (as determined by the investigator) in a tucatinib Parent Study.\n2. Agree to follow the reproductive criteria.\n3. Be willing and able to comply with all scheduled visits, treatment plan, and other study procedures as outlined in this protocol.\n4. Be capable of giving signed informed consent.\n\nExclusion Criteria:\n\n1. Any medical reason that, in the opinion of the investigator or sponsor, precludes the participant from inclusion in the study.\n2. Current use of any prohibited concomitant medications(s) or unwillingness or inability to use a required concomitant medication(s).\n3. Participants not previously enrolled or who have discontinued study intervention or who were randomized in the control arm in a Parent Study.",{"count":455,"type":21},175,[457],"PHASE4","The purpose of this protocol is to give continued access to tucatinib eligible participants. It also enables ongoing safety follow-up for those who continue to benefit from the study treatment. These participants were part of Pfizer-sponsored tucatinib parent studies that will be closed. Additional follow-up safety information will be collected. This will allow further understanding of the safety profile of tucatinib in participants who continue to receive the study treatment.",[460,66,461,288,462,463,33],"HER2-positive Breast Cancer","Biliary Tract Neoplasms","Advanced Non-Small Cell Lung Cancer","Gastric or Gastroesophageal Junction Adenocarcinoma (GEC)",[465],"tucatinib","2026-08-12",{"date":220,"type":38},{"date":469,"type":21},"2026-08-24",{"date":471,"type":21},"2032-03-13",{"name":473,"class":89},"Pfizer",{"id":475,"slug":476,"hasResults":12,"nctId":477,"briefTitle":478,"officialTitle":479,"acronym":4,"eligibilityCriteria":480,"healthyVolunteers":481,"sex":17,"minAge":18,"maxAge":482,"enrollmentInfo":483,"targetDuration":4,"studyType":22,"phases":484,"briefSummary":485,"conditions":486,"keywords":488,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":466,"lastUpdatePostDateStruct":492,"startDateStruct":493,"completionDateStruct":494,"leadSponsor":496,"locationsCount":46},"100651421","novel-couple-based-mindfulness-intervention-for-metastatic-colorectal-cancer-100651421","NCT07759921","Novel Couple-Based Mindfulness Intervention for Metastatic Colorectal Cancer","Feasibility and Acceptability of a Novel Couple-Based Mindfulness Intervention for Metastatic Colorectal Cancer: A Pilot Randomized Controlled Trial","Inclusion Criteria:\n\n* Provision to sign and date the consent form.\n* Stated willingness to comply with all study procedures and be available for the duration of the study.\n* Be aged \\> 18 years to 85.\n* Fluent in English language. All study materials, including the informed consent form, participant workbooks, and questionnaires, are currently available only in English. Participation requires the ability to independently read and engage with written study materials (including the participant workbook), which are integral to the intervention session content and home practices. Therefore, individuals who are unable to read study materials in English are not eligible to participate. At this time, the intervention has not been translated or validated in other languages, therefore participation is limited to individuals who can read, speak, and understand English to ensure that participants are able to fully engage with study activities.\n* Be a person (i.e., patient) diagnosed with metastatic colorectal cancer (mCRC) or a partner (e.g., spouse) of someone diagnosed with mCRC.\n* Indicates a score \\>0 on the Distress Thermometer\n* Has access to computer\u002Finternet through with video-conferencing (phone, laptop, tablet, desktop computer)\n\nAdditional eligibility criteria include:\n\nAdditional patient participant inclusion criteria:\n\n* Has a current diagnosis of metastatic (Stage IV, recurrent) colorectal cancer\n* Has an ECOG status \\\u003C2 or otherwise deemed appropriate for study participation by a clinician\n* Is in a committed relationship with a romantic partner for \\>6 months. Monogamy is not required for eligibility; however, in cases of polyamorous relationships, the patient will designate a primary partner for participation in the study.\n\nAdditional partner participant inclusion criteria:\n\n• Has been in a committed relationship \\>6 months with a patient who meets the above eligibility criteria\n\nEligibility for relationship status will be self-reported by participants during recruitment.\n\nExclusion Criteria:\n\n* One or both members of the couple has an active or poorly controlled serious mental illness (e.g., psychotic disorder), cognitive impairment (e.g., dementia), or medical condition (e.g., significant impaired sight\u002Fhearing) that would compromise participation.\n* The couple is currently in active couples (e.g., marital) therapy together.\n\nParticipants who are physically or mentally too ill to participate or those with major cognitive impairments are excluded because they may not be able to engage with intervention sessions, surveys. No exclusions will be made based on sexual orientation, race, gender, or other sociodemographic features. Because patients with mCRC are living longer, and patients and partners can experience distress at various times since their diagnosis, we do not limit participation by time since diagnosis.",true,"85 Years",{"count":99,"type":21},[122],"The overall objective of this study is to learn whether a newly developed couple-based mindfulness program (Mindful PaCT) is practical to complete (feasible), helpful and well-received (acceptable), and relevant for patients with metastatic colorectal cancer (mCRC) and their partners.",[33,487],"Metastatic Colorectal Cancer (CRC)",[489,490,491],"Couple","Partner","Caregiver",{"date":289,"type":38},{"date":377,"type":21},{"date":495,"type":21},"2030-12",{"name":497,"class":45},"University of Colorado, Denver",{"id":499,"slug":500,"hasResults":12,"nctId":501,"briefTitle":502,"officialTitle":503,"acronym":4,"eligibilityCriteria":504,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":505,"targetDuration":4,"studyType":22,"phases":507,"briefSummary":508,"conditions":509,"keywords":512,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":466,"lastUpdatePostDateStruct":518,"startDateStruct":519,"completionDateStruct":521,"leadSponsor":522,"locationsCount":524},"100598066","phase-1-a-study-of-mrg007-arr-217-in-patients-with-advanced-solid-tumors-100598066","NCT07066657","A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors","An Open-Label, Multi-Center, Dose Escalation, Confirmation, and Expansion Phase I Clinical Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of MRG007 (ARR-217) in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors","1. Willing to sign the informed consent form and follow the requirements specified in the protocol.\n2. Life expectancy ≥ 3 months.\n3. Tumor specimen available for CDH17 testing, or agree to biopsy at baseline.\n4. Patients with histologically and cytologically confirmed advanced or metastatic solid tumor who have failed or intolerant to standard therapy, or without alternative standard therapy.\n5. Patients must have at least one measurable lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST v1.1).\n6. The score of ECOG for performance status is 0 or 1.\n7. Organ functions and coagulation function must meet the basic requirements.\n8. Patients with childbearing potential must use effective contraception during the treatment and for 6 months after the last dose of treatment.\n\nExclusion Criteria:\n\n1. Patients with more than one cancer.\n2. Received CDH17-targeting anti-tumor therapy; received other investigational product, systemic corticosteroids or surgery for major organs within 4 weeks prior to the first dose; received anti-tumor therapy within 3 weeks or within 5 half-lives prior to the first dose, whichever is shorter; received radiotherapy within 2 weeks prior to the first dose; received strong CYP3A4 inducers or inhibitors within 2 weeks prior to the first dose or 5 half-lives, whichever is longer; investigational therapy within 4 weeks or 5 half-lives (whichever is shorter) prior to the first dose.\n3. ≥Grade 2 toxic reaction or abnormal value of laboratory test caused by previous anti-tumor treatment\n4. Symptomatic Central nervous system and\u002For meninges metastasis.\n5. History of severe cardiovascular diseases\n6. Cerebrovascular accident, pulmonary embolism, or deep venous thrombosis within 3 months prior to the first dose, implantable venous infusion port or catheter-related thrombosis, or superficial venous thrombosis\n7. History of previous or combined interstitial pneumonia, current interstitial pneumonia, or suspected interstitial pneumonia that cannot be ruled out through imaging during screening, severe chronic obstructive pulmonary disease with respiratory failure, severe pulmonary dysfunction, symptomatic bronchospasm, etc.\n8. Poorly controlled pleural, peritoneal, and pelvic effusion, or combined pericardial effusion\n9. Infection of active hepatitis B, active hepatitis C, or HIV\n10. Uncontrolled active bacterial, viral, fungal, rickettsial, or parasitic infections requiring intravenous anti-infection therapy within 2 weeks prior to the first study treatment\n11. Known allergic reactions to any component of MRG007, or known Grade≥3 allergic reactions to other prior anti-CDH17 (including investigational) or other monoclonal antibody.\n12. Other situations that are not suitable to participate a clinical trial per investigator's judgement\n13. Additional protocol-defined exclusion criteria apply",{"count":506,"type":21},572,[24],"This is an open-label, multi-center, phase I study to evaluate the safety, tolerability, efficacy, and pharmacokinetics of MRG007 (ARR-217) in patients with unresectable locally advanced or metastatic solid tumors.",[510,33,158,511],"Locally Advanced or Metastatic Solid Tumors","Pancreatic Cancer",[513,514,515,516,517],"MRG007","Advanced or Metastatic Solid Tumors","CDH17","ARR-217","ADC",{"date":354,"type":38},{"date":520,"type":38},"2025-07-25",{"date":495,"type":21},{"name":523,"class":89},"ArriVent BioPharma, Inc.",21,{"id":526,"slug":527,"hasResults":12,"nctId":528,"briefTitle":529,"officialTitle":530,"acronym":4,"eligibilityCriteria":531,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":532,"enrollmentInfo":533,"targetDuration":4,"studyType":22,"phases":535,"briefSummary":536,"conditions":537,"keywords":539,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":466,"lastUpdatePostDateStruct":545,"startDateStruct":546,"completionDateStruct":548,"leadSponsor":550,"locationsCount":552},"100476843","phase-2-study-of-dato-dxd-as-monotherapy-and-in-combination-with-anti-cancer-agents-in-patients-with-advanced-solid-tumours-tropion-pantumor03-100476843","NCT05489211","Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)","A Phase II, Multicentre, Open-label, Master Protocol to Evaluate the Efficacy and Safety of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination With Anticancer Agents in Patients With Advanced\u002FMetastatic Solid Tumours","Key Inclusion Criteria: There are additional substudy requirements not reflected here. This list is based solely on the master CSP\n\n* Male and female, ≥ 18 years\n* Documented advanced or metastatic malignancy\n* Eastern Cooperative Oncology Group performance status of 0 or 1 with no deterioration over the 2 weeks prior to baseline or day of first dosing\n* All participants must provide a tumour sample for tissue-based analysis\n* At least 1 measurable lesion not previously irradiated, except Substudy 3 (Prostate Cancer) which allows participants with non measurable bone metastatic disease\n* Adequate bone marrow reserve and organ function\n* Minimum life expectancy of 12 weeks\n* At the time of screening, contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies\n* All women of childbearing potential must have a negative serum pregnancy test documented during screening\n* Female participants must be 1 year post-menopausal, surgically sterile, or using 1 highly effective form of birth control. Female participants must not donate, or retrieve for their own use, ova at any time during this study\n* Male participants who intend to be sexually active with a female partner of childbearing potential must be surgically sterile, avoid intercourse, or use a highly effective method of contraception. Male participants must not freeze or donate sperm at any time during this study.\n* Capable of giving signed informed consent\n* Provision of signed and dated written optional genetic research informed consent prior to collection of samples for optional genetic research that supports the Genomic Initiative\n\nKey Exclusion Criteria:\n\n* Any evidence of diseases which, in the investigator's opinion, makes it undesirable for the participant to participate in the study or that would jeopardize compliance with the protocol\n* History of another primary malignancy except for adequately resected basal cell carcinoma or in situ squamous cell carcinoma of the skin, or other solid malignancy treated with curative intent\n* Persistent toxicities caused by previous anticancer therapy, excluding alopecia, not yet improved\n* Irreversible toxicity that is not reasonably expected to be exacerbated by study intervention in the opinion of the investigator, for example hearing loss\n* Spinal cord compression or brain metastases unless treated\n* Leptomeningeal carcinomatosis\n* Clinically significant corneal disease\n* Active hepatitis or uncontrolled hepatitis B or C virus infection\n* Uncontrolled infection requiring IV antibiotics, antivirals or antifungals, for example prodromal symptoms\n* Known HIV infection that is not well controlled\n* Known active tuberculosis infection\n* Mean resting corrected QTcF \\> 470 ms\n* In the judgement of the investigator, history of QT prolongation associated with other medications that required discontinuation of that medication, or any current concomitant medication known to prolong the QT interval and cause TdP\n* In the judgement of the investigator, congenital long QT syndrome, family history of long QT syndrome, or unexplained sudden death under 40 years of age in first-degree relatives\n* Uncontrolled or significant cardiac diseases\n* History of non-infectious Interstitial lung disease (ILD)\u002Fpneumonitis, including radiation pneumonitis that required steroids\n* Has severe pulmonary function compromise\n* Prior exposure to chloroquine\u002Fhydroxychloroquine without an adequate treatment washout period\n* Receipt of live, attenuated vaccine within 30 days prior to the first dose of study intervention\n* Prior exposure to anticancer therapies without an adequate treatment washout period prior to enrolment or any concurrent anticancer treatment\n* Palliative radiotherapy with a limited field of radiation within ≤ 2 weeks or to more than 30% of the bone marrow within ≤ 4 weeks before the first dose of study intervention\n* Major surgical procedure or significant traumatic injury within ≤ 3 weeks of the first dose of study intervention or an anticipated need for major surgery during the study\n* Prior treatment with TROP2-directed therapies or other antibody-drug conjugate (ADCs) with deruxtecan payload\n* Herbal or natural products intended as treatment or prophylaxis for any type of cancer that may interfere with the activity of the study intervention\n* Previous treatment in the present study\n* Participation in another clinical study with a study intervention or investigational medicinal device administered in the last 4 weeks prior to first dose of study intervention or concurrent enrolment in another clinical study\n* Severe hypersensitivity to Dato-DXd or any of the excipients, including but not limited to polysorbate 80 or other monoclonal antibodies\n* Involvement in the planning and\u002For conduct of the study\n* Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements\n* Females that are pregnant, breastfeeding, or planning to become pregnant\n* Female participants should refrain from breastfeeding from enrolment throughout the study and for at least 7 months after last dose of Dato-DXd","130 Years",{"count":534,"type":21},454,[25],"TROPION-PanTumor03 will investigate the safety, tolerability, and anti-tumour activity of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced\u002FMetastatic Solid Tumours.",[65,158,425,80,33,288,538],"Biliary Tract Cancer",[540,541,542,543,544],"TROPION-PanTumor03","Datopotamab Deruxtecan (Dato-DXd)","Solid Tumours","Antibody-drug conjugate (ADC)","Trophoblast cell surface protein 2 (TROP2)",{"date":354,"type":38},{"date":547,"type":38},"2022-09-06",{"date":549,"type":21},"2027-10-01",{"name":551,"class":89},"AstraZeneca",96,{"id":554,"slug":555,"hasResults":12,"nctId":556,"briefTitle":557,"officialTitle":558,"acronym":4,"eligibilityCriteria":559,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":560,"targetDuration":4,"studyType":22,"phases":562,"briefSummary":563,"conditions":564,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":466,"lastUpdatePostDateStruct":567,"startDateStruct":568,"completionDateStruct":570,"leadSponsor":572,"locationsCount":574},"100461404","phase-1-phase-12a-study-of-jab-21822-plus-jab-3312-in-patients-with-advanced-solid-tumors-harboring-kras-pg12c-mutation-100461404","NCT05288205","Phase 1\u002F2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation","A Phase 1\u002F2a Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of JAB-21822 in Combination With JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation","Inclusion Criteria:\n\n* A written informed consent should be signed by a subject or his\u002Fher legal representative before any study-related procedures are performed;\n* Subjects with histologically or cytologically confirmed locally advanced or metastatic advanced solid tumors harboring KRAS p.G12C mutation who have failed or lack standard-of-care (SOC) or are unwilling to undergo or intolerant to SOC;\n* Expected survival ≥ 3 months;\n* Subjects must have at least one measurable lesion as defined by RECIST v1.1. If no measurable lesion untreated with radiation is selected as the target lesion, a lesion treated with radiation ≥ 4 weeks before the first dose and with progression confirmed by radiography may be selected as the target lesion;\n* Eastern Cooperative Oncology Group(ECOG) performance status 0-1;\n* The organ functions of subjects meet the criteria for the following laboratory parameters at screening;\n* Subjects must be able to swallow oral medications without gastrointestinal abnormalities that significantly affect drug absorption\n\nExclusion Criteria:\n\n* Patients with previous (≤ 3 years) or current tumors of other pathological types, except for cured cervical carcinoma in situ, ductal carcinoma in situ of the breast, prostatic intraepithelial neoplasia, superficial non-invasive bladder cancer, stage I skin cancer (except melanoma); subjects without recurrence or metastasis for \\> 3 years after treatment, without current evidence of tumor, and without significant risk of recurrence of previous malignant diseases in the opinion of the study doctor may also be enrolled;\n* Serious allergy to the investigational drug or excipients (such as microcrystalline cellulose, etc.);\n* Patients with previous (≤ 6 months before the initiation of treatment) or current severe autoimmune diseases (including adverse reactions caused by previous anti- tumor immunotherapies), or autoimmune diseases requiring long-term systemic hormone therapy at immunosuppressive dose levels (prednisone \\> 10 mg\u002Fday or equivalent drugs);\n* HIV, hepatitis B virus(HBV), or hepatitis C virus(HCV) positive;\n* Previous (≤ 6 months prior to the first dose) or current evidence of the following diseases: acute myocardial infarction, unstable angina and cerebrovascular accident;\n* Subjects who have impaired cardiac functions or clinically significant cardiac diseases;\n* Pregnant or lactating women",{"count":561,"type":21},240,[24,25],"This is a multicenter, open-label phase 1\u002F2a study consisting of two parts: dose escalation phase and dose expansion phase. The objective of the dose escalation phase is to evaluate the safety, tolerability and pharmacokinetics of JAB-21822 in combination with JAB-3312 in patients with advanced solid tumors harboring KRAS p.G12C mutation and to determine the RP2D for the combination therapy. In the dose expansion phase, preliminary efficacy and safety of the combination therapy at the RP2D will be further explored in patients with specific cancer harboring KRAS p.G12C mutation.",[565,61,33,566],"KRAS P.G12C","Pancreatic Ductal Carcinoma",{"date":354,"type":38},{"date":569,"type":38},"2022-04-14",{"date":571,"type":21},"2027-03",{"name":573,"class":89},"Allist Pharmaceuticals, Inc.",27,{"id":576,"slug":577,"hasResults":12,"nctId":578,"briefTitle":579,"officialTitle":580,"acronym":581,"eligibilityCriteria":582,"healthyVolunteers":12,"sex":17,"minAge":234,"maxAge":583,"enrollmentInfo":584,"targetDuration":4,"studyType":154,"phases":4,"briefSummary":586,"conditions":587,"keywords":588,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":593,"lastUpdatePostDateStruct":594,"startDateStruct":595,"completionDateStruct":597,"leadSponsor":599,"locationsCount":46},"100572815","microbiome-based-diagnostic-tool-for-the-screening-of-colorectal-cancer-guilti-100572815","NCT06738173","Microbiome-based Diagnostic Tool for the Screening of Colorectal Cancer (GUILTI)","A Gut Microbiome-based Diagnostic Tool for the Screening of Colorectal Cancer","GUILTI","Inclusion Criteria:\n\n* Patients participating in the national CRC screening program (50-74 years old)\n* Positivity to the FIT;\n* Ability to provide written informed consent and to be compliant with the study procedures.\n\nExclusion Criteria:\n\n* Patients unfit for colonoscopy;\n* Other oncological conditions;\n* Concomitant severe comorbidities or gastrointestinal (GI) organic diseases (e.g. diverticular disease, inflammatory bowel disease);\n* Antibiotics, proton pump inhibitors or probiotics within 4 weeks prior to enrollment.","74 Years",{"count":585,"type":21},1202,"Colorectal cancer (CRC) is one of the most common cancer and cause of cancer death worldwide. Population-based screening programs for average risk populations have proven effective in reducing both incidence and mortality of CRC through early detection of cancer. The fecal immunochemical testing (FIT), has still a suboptimal diagnostic yield, with both missed adenomas and, mainly, unnecessary colonoscopies.The identification of novel, non-invasive biomarkers is currently one of the research areas driving most expenditure forces in the field of CRC.A large body of evidence shows that alterations of the gut microbiome and the enrichment of specific taxa(e.g. Fusobacterium nucleatum, Parvimonas micra, and others) are involved in the pathogenesis of CRC. Moreover, recent studies, have discovered common microbial signatures able to reproducibly discriminate between patients with CRC and healthy controls.The goal of this observational study to develop a gut microbiome based diagnostic tool for the identification of CRC and advanced colorectal adenomas in patients enrolled in the national colorectal cancer (CRC) screening program (50-74 year-old) and among who refer to all centers involved in this study for screening colonoscopy with positivity of FIT, of both sex. The primary endpoint of the study is to develop a gut microbiome-based diagnostic tool for the identification of CRC and advanced colorectal adenomas in patients involved in the national CRC screening program, using both statistical and machine learning approaches. The secondary endpoints are:\n\n* The association of clinical and colonoscopy outcomes with FIT results;\n* The characterization of gut microbiome from an ecological, taxonomic, phylogenetic and functional point of view;\n* The association between microbiome signatures with clinical and colonoscopy outcomes, through statistical and machine-learning algorithms. At baseline, enrolled patients will provide a fecal sample within 2 weeks from enrollment and demographic, clinical characteristics and laboratory data will be recorded. Enrolled patients will be scheduled for colonoscopy, as for clinical practice, within 4 weeks from the positive FIT and histology of resected lesions will be assessed by experienced pathologists according to the WHO classification and the Vienna criteria. Clinical, endoscopic and microbial data will be combined through statistical and machine learning algorithms to identify specific microbial biomarkers associated with CRC and develop a new diagnostic tool, based on a scoring system. This tool will be validated, and its diagnostic performances will be compared with traditional screening methods.",[33],[589,590,591,592],"microbiome testing","microbiome","colorectal cancer screening","colorectal cancer","2026-08-11",{"date":354,"type":38},{"date":596,"type":38},"2025-02-07",{"date":598,"type":21},"2029-09-30",{"name":600,"class":45},"Catholic University of the Sacred Heart",{"id":602,"slug":603,"hasResults":12,"nctId":604,"briefTitle":605,"officialTitle":606,"acronym":607,"eligibilityCriteria":608,"healthyVolunteers":12,"sex":17,"minAge":234,"maxAge":583,"enrollmentInfo":609,"targetDuration":4,"studyType":154,"phases":4,"briefSummary":611,"conditions":612,"keywords":613,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":593,"lastUpdatePostDateStruct":614,"startDateStruct":615,"completionDateStruct":617,"leadSponsor":619,"locationsCount":46},"100561284","microbiome-testing-for-the-screening-of-colorectal-cancer-100561284","NCT06588166","Microbiome Testing for the Screening of Colorectal Cancer","A Non-invasive Gut Microbiome-based Diagnostic Tool for the Screening of Colorectal Cancer","NI-GUILTI","Inclusion Criteria:\n\n* Patients participating in the national CRC screening program (50-74 years old)\n* Positivity to the FIT;\n* Ability to provide written informed consent and to be compliant with the study procedures\n\nExclusion Criteria:\n\n* Patients unfit for colonoscopy;\n* Other oncological conditions;\n* Concomitant severe comorbidities or gastrointestinal (GI) organic diseases (e.g. diverticular disease, inflammatory bowel disease);\n* Antibiotics,proton pump inhibitors or probiotics within 4 weeks prior to enrollment.",{"count":610,"type":21},1006,"Colorectal cancer (CRC) is one of the most common cancer and cause of cancer death worldwide. Population-based screening programs for average-risk populations have proven effective in reducing both incidence and mortality of CRC through early detection of cancer. The fecal immunochemical testing (FIT), has still a suboptimal diagnostic yield, with both missed adenomas and, mainly, unnecessary colonoscopies.The identification of novel, non-invasive biomarkers is currently one of the research areas driving most expenditure forces in the field of CRC.A large body of evidence shows that alterations of the gut microbiome and the enrichment of specific taxa(e.g. Fusobacterium nucleatum, Parvimonas micra, and others) are involved in the pathogenesis of CRC. Moreover, recent studies, have discovered common microbial signatures able to reproducibly discriminate between patients with CRC and healthy controls.\n\nThe goal of this observational study to develop a gut microbiome-based diagnostic tool for the identification of CRC and advanced colorectal adenomas in patients enrolled in the national colorectal cancer (CRC) screening program (50-74 years old) and among who refer to all centers involved in this study for screening colonoscopy with positivity of FIT, of both sex.\n\nThe primary endpoint of the study is to develop a gut microbiome-based diagnostic tool for the identification of CRC and advanced colorectal adenomas in patients involved in the national CRC screening program at 30 months, using both statistical and machine learning approaches\n\nThe secondary endpoints are:\n\n* The association of clinical and colonoscopy outcomes with FIT results at 30 months\n* The characterization of gut microbiome from an ecological, taxonomic, phylogenetic and functional point of view at 30 months\n* The association between microbiome signatures with clinical and colonoscopy outcomes at 30 months, through statistical and machine-learning algorithms At baseline, enrolled patients will provide a fecal sample within 2 weeks from enrollment and demographic, clinical characteristics and laboratory data will be recorded. Enrolled patients will be scheduled for colonoscopy, as for clinical practice, within 4 weeks from the positive FIT and histology of resected lesions will be assessed by experienced pathologists according to the WHO classification and the Vienna criteria.\n\nClinical, endoscopic and microbial data will be combined through statistical and machine learning algorithms to identify specific microbial biomarkers associated with CRC and develop a new diagnostic tool, based on a scoring system.\n\nThis tool will be validated, and its diagnostic performances will be compared with traditional screening methods.",[33],[590,589,592,591],{"date":354,"type":38},{"date":616,"type":38},"2024-11-29",{"date":618,"type":21},"2027-02-28",{"name":620,"class":45},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":622,"slug":623,"hasResults":12,"nctId":624,"briefTitle":625,"officialTitle":626,"acronym":627,"eligibilityCriteria":628,"healthyVolunteers":12,"sex":17,"minAge":118,"maxAge":629,"enrollmentInfo":630,"targetDuration":4,"studyType":22,"phases":632,"briefSummary":633,"conditions":634,"keywords":639,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":593,"lastUpdatePostDateStruct":642,"startDateStruct":643,"completionDateStruct":645,"leadSponsor":647,"locationsCount":649},"100486305","colonoscopy-vs-stool-testing-for-older-adults-with-colon-polyps-100486305","NCT05612347","Colonoscopy vs Stool Testing for Older Adults With Colon Polyps","Colonoscopy Versus Stool-based Testing for Older Adults With a History of Colon Polyps","COOP","Inclusion Criteria:\n\n* English or Spanish speaking\n* Personal history of colorectal polyps\n* Most recent colonoscopy with ≤2 non-advanced polyps\n* Currently due or coming due within 12 months for colonoscopy\n* Able to provide written informed consent\n\nExclusion Criteria:\n\n* Personal history of colorectal cancer\n* Personal history of genetic syndrome with high risk for colorectal cancer (e.g. Lynch Syndrome, Familial Adenomatous Polyposis Syndrome (FAP), or Serrated Polyposis Syndrome)\n* Personal history of inflammatory bowel disease (e.g. ulcerative colitis, Crohn's disease)\n* Most recent colonoscopy with advanced polyp(s) or ≥3 non-advanced polyps\n* Patients unlikely to benefit from polyp surveillance (e.g., history of heart disease or coronary artery disease with treatment in the last 6 months, heart failure affecting function, lung disease requiring use of home oxygen, stroke within the last 4 months, dementia affecting activities of daily living (ADL) or instrumental activities of daily living (IADL), severe liver disease requiring the use of certain medications to control fluid, confusion, or bleeding, severe kidney disease requiring dialysis, or a new cancer diagnosis within the last year)\n* Patients unable to provide written informed consent","82 Years",{"count":631,"type":21},8946,[122],"This is a multi-site comparative effectiveness randomized controlled trial (RCT) comparing annual fecal immunochemical testing (FIT) and colonoscopy for post-polypectomy surveillance among adults aged 65-82 with a history of colorectal polyps who are due for surveillance colonoscopy.",[635,636,637,33,638],"Colorectal Polyp","Colorectal Neoplasms","Colorectal Adenoma","Digestive System Disease",[640,641],"Colonoscopy","Fecal immunochemical test (FIT)",{"date":354,"type":38},{"date":644,"type":38},"2023-06-14",{"date":646,"type":21},"2035-12-31",{"name":648,"class":45},"Dartmouth-Hitchcock Medical Center",24,{"id":651,"slug":652,"hasResults":12,"nctId":653,"briefTitle":654,"officialTitle":655,"acronym":4,"eligibilityCriteria":656,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":657,"targetDuration":4,"studyType":22,"phases":659,"briefSummary":660,"conditions":661,"keywords":663,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":671,"lastUpdatePostDateStruct":672,"startDateStruct":673,"completionDateStruct":675,"leadSponsor":677,"locationsCount":46},"100651825","a-one-year-follow-up-of-incisional-hernia-formation-between-device-assisted-and-manual-laparotomy-closure-100651825","NCT07766044","A One-year Follow-up of Incisional Hernia Formation Between Device Assisted and Manual Laparotomy Closure","A One-year Follow-up Comparison of Incisional Hernia Formation Between Device Assisted and Manual Closure in Patients Undergoing Elective Laparotomy for Colorectal Diseases","Inclusion Criteria:\n\n* \\>18 years of age\n* Patients selected for elective surgical procedure through a midline incision due to colorectal disease\n\nExclusion Criteria:\n\n* Previous surgery including the midline\n* Previous hernia including the midline\n* Collagen disease\n* Disseminated disease at the time of surgery\n* Life expectancy less than 1 year.",{"count":658,"type":21},218,[122],"The study compares one-year incisional hernia formation between two cohorts of patients that underwent open surgery for colorectal diseases. The patients had the abdominal wall closure performed with either a device for standardized closure or manual closure.\n\nThe devices aims to secure the closure technique that is advocated by guidelines and could potentially reduce abdominal wall complications. Upholding closure quality can be cumbersome and time consuming and hence inferior closure can sometimes be associated with manual closure.\n\nFollow-up will include short term complications like wound infection and burst abdomen and one-year follow-up include a review of patients chart and CTscans performed as part of standard clinical practice.",[662,33],"Incisional Hernia After Midline Laparotomy",[664,665,666,667,668,669,670],"Laparotomy","Incisional hernia","Device assisted closure","Small-bites","Burst abdomen","Wound infection","Laparotomy closure","2026-08-10",{"date":289,"type":38},{"date":674,"type":38},"2026-07-18",{"date":676,"type":21},"2026-12-30",{"name":678,"class":89},"Suturion AB"]